In January 2023, the Board of Directors approved a restructuring plan (referred to as the “2023 Plan”) and the Company announced the consolidation of the ITIL-306 Phase 1 clinical trial and related manufacturing of CoStAR-TIL to its operations in Manchester, UK and stopped recruiting for the ITIL-306 clinical trial.

In January 2024, the Board of Directors approved a comprehensive restructuring plan, which included the closure of the Company’s UK manufacturing facility and clinical trial operations. In September 2024, the Board of Directors approved additional UK restructuring actions, which resulted in the elimination of the majority of the remaining UK workforce in the fall of 2024, with the remaining reduction and restructuring activities substantially completed by the end of 2024. Collectively, these actions are referred to as the “2024 Plan.”

As a result of the Plan and listing the Tarzana facility for sale, the Company recorded charges of $16.6 million and $7.5 million within the consolidated statements of operations and comprehensive loss in the line item “restructuring and impairment charges” for the years ended December 31, 2025 and 2024, respectively.

These charges relate to asset impairments, contract terminations, severance payments, employee-related costs and other gains incurred. The following table summarizes the restructuring and impairment (gain) loss by category (in thousands):


	Year Ended December 31,
	2025		2024
Asset impairment for leasehold improvements	$	—	$	343
One-time employee termination benefits	—		2,721
Contract terminations	53		(723)
Right-of-use asset impairment	—		827
Impairment of long-lived assets held for sale	16,569		4,325
Total restructuring and impairment charges	$	16,622	$	7,493

As a result of the Plan, the restructuring liability was recorded in the consolidated balance sheets under “Accrued expenses and other current liabilities” and was measured at the amount expected to be paid, or that was paid. During the year ended December 31, 2025, the Company paid $1.4 million of restructuring costs, and expects to pay the remainder of the restructuring costs by December 31, 2026.


	Employee Benefits		Contract Terminations		Total
Restructuring liability as of December 31, 2023	$	—	$	3,136	$	3,136
Additions, net	2,420		733		3,153
Payments	(2,289)		(578)		(2,867)
Adjustments	—		(1,349)		(1,349)
Restructuring liability as of December 31, 2024	$	131	$	1,942	$	2,073
Payments	(131)		(1,300)		(1,431)
Adjustments	—		(487)		(487)
Total restructuring liability as of December 31, 2025	$	—	$	155	$	155